The Relationship Between Body Composition and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Authors:
Open Access
- 26 May 2024
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 16 (5) , e61145
Abstract
Background The pathological response rate in operable breast cancer (BC) patients receiving neoadjuvant chemotherapy (NAC) is postulated to be related to body composition. The success of complete pathological response (pCR) is a known prognostic factor in BC patients treated with NAC. We aimed to accurately measure body composition through BMI and skeletal muscle mass and observe their effects on pCR. Materials and methods Patients diagnosed with operable BC who had a positron emission tomography-computed tomography (PET-CT) or chest/abdominal CT taken at the time of diagnosis were retrospectively screened and enrolled in this study. Muscle mass was defined by third lumbar vertebra (L3) level transverse CT images, and data, including weight and height, were collected from the chemotherapy records. All these data were evaluated together with the postoperative pathological results. Results Sixty-nine operable BC patients with a median age of 46 (range: 29-72) years were included in the study. In all patients, regardless of sarcopenia, 23% (n = 16) achieved pCR to NAC. The pCR rate was 37.5% (n=6) in sarcopenic patients and 62.5% (n=10) in non-sarcopenic patients (p = 0.530). Overweight (n=4; 25%) and obese (n=2; 12.5%) patients also had a lower pathological response than normal-weight (n=10; 62.5%) BC patients (p=0.261). Conclusion Both sarcopenia and obesity independently and synergistically contribute to poorer pathological responses after NAC. Addressing these conditions through tailored interventions, such as nutritional support, exercise programs, and careful monitoring of body composition, could improve treatment outcomes. Further research with larger patient populations and comprehensive body measurements is essential to fully understand these relationships and develop effective strategies to mitigate their impact.Keywords
This publication has 23 references indexed in Scilit:
- Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?The Breast, 2021
- Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast CancerJAMA Oncology, 2018
- The obesity paradox in cancer: clinical insights and perspectivesEating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2018
- BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-AnalysisClinical Breast Cancer, 2016
- Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trialsBreast Cancer Research and Treatment, 2015
- The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patientsThe Breast, 2014
- ‘Metabolically healthy obesity’: Origins and implicationsMolecular Aspects of Medicine, 2013
- Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL StudyJournal of Cancer Survivorship, 2012
- The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imagingJournal of Surgical Oncology, 2009
- Body size and breast cancer prognosis: A critical review of the evidenceBreast Cancer Research and Treatment, 1990